SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF
申请人:Araxes Pharma LLC
公开号:US20170022184A1
公开(公告)日:2017-01-26
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I):
or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein R, R
1
, R
2a
, R
2b
, R
2c
, A, B, L
1
and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.
Takahashi, Tamiko; Hirokami, Shun-ichi; Nagata, Masanori, Journal of the Chemical Society. Perkin transactions I, 1989, p. 1231 - 1239
Site isolated base and acid catalyzed azaspirocyclization cascades
作者:Adam W. Pilling、Jutta Böhmer、Darren J. Dixon
DOI:10.1039/b716568d
日期:——
A one-pot, site isolated base (PS-BEMP) and acid (Si-TsOH) catalyzed cyclization cascade to azaspirocyclic molecules is reported; the reaction is simple to perform, atom efficient (water is the only byproduct) and broad in its scope to a diverse range of azaspirocyclic products.